Form 4: PTC Therapeutics CFO Sells Shares for Tax Obligations

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,139 shares of common stock at $76.95 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Pierre Gravier, Chief Financial Officer of PTC Therapeutics, Inc. (PTCT), reported a sale of common stock.
• The transaction involved the disposition of 2,139 shares of common stock on January 6, 2026.
• The shares were sold at a price of $76.95 per share.
• The sale was executed automatically pursuant to an irrevocable 'sell to cover' election, intended to satisfy tax withholding obligations.
• This 'sell to cover' was in connection with the vesting of 5,625 Restricted Stock Units (RSUs) from a larger grant of 22,500 RSUs made on January 3, 2025.
• Following this transaction, Pierre Gravier beneficially owns 90,310 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax withholding purposes related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction is generally considered neutral and does not reflect management's discretionary view on the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, common across all industries for executives receiving equity awards. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or a significant shift in ownership.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' to satisfy tax obligations upon RSU vesting, executed under a Rule 10b5-1 plan. This is a common and routine event for executives and does not signal any change in the company's fundamentals, management's outlook, or the investment thesis. Therefore, it provides no basis to alter an existing 'hold' recommendation.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Stock Sale, CFO, Pierre Gravier, RSU Vesting, Tax Withholding, 10b5-1 Plan